Details of the Drug Reposition

General Information of This Drug (ID: DMVOY6B)

Drug Name
AMD-070   DMVOY6B
Synonyms
AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Whim syndrome DIS8J18X 4A00.Y Phase 3 [1]
------------------------------------------------------------------------------------
5 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Human immunodeficiency virus infection DISRNAI4 1C62 Phase 1/2 [2]
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1/2 [3]
Melanoma DIS1RRCY 2C30 Phase 1/2 [3]
Merkel cell carcinoma DISDJJ4U 2C34 Phase 1/2 [3]
Renal cell carcinoma DISQZ2X8 2C90 Phase 1/2 [3]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03995108) Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome. U.S. National Institutes of Health.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8580).
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)